Grifois

GRFS

Market cap $5.98B

Grifols (GRFS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Grifols, S.A. (OTCPK:GIKLY) Q3 2025 Earnings Call November 4, 2025 12:30 PM EST Company Participants Daniel Segarra - Head of Investor Relations & Sustainability and Vice President Jose Ignacio Abia Buenache - CEO & Director Roland Wandeler - President of Biopharma Business Unit Rahul Srinivasan - Chief Financial Officer Conference Call Participants Charles Pitman - Barclays Bank PLC, Research Division Jaime Escribano - Banco Santander, S.A.

Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launching premature IPOs.

Here is how Grifols (GRFS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

The current market is all about momentum, but investors don't need to buy overpriced high-growth stocks to participate in gains. If you dig deep enough, you can find undervalued stocks with growth potential in both the short term and the long run. Across varied sectors like healthcare, technology, and finance, as well as non-U.S. countries with growth potential, a select group of stocks can combine those qualities.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Spain's High Court on Thursday summoned the founder of U.S.-based short seller Gotham City Research, Daniel Yu, to testify over allegations his company disseminated misleading information about pharma firm Grifols to influence its share price.